改良抗血栓指南对儿童心室辅助装置支持者卒中的影响
该研究比较了斯坦福大学2009至2014年使用柏林心脏EXCOR儿童心室辅助装置的患儿,按抗血栓指南分为埃德蒙顿指南组和斯坦福改良指南组。结果显示改良指南组卒中发生率显著降低84%,出血率也更低,且不增加出血风险。
要点
- 斯坦福改良指南采用三联抗血小板治疗并按体重高剂量滴定,卒中发生率降低84%。
- 改良指南组出血率更低,目标剂量阿司匹林、氯吡格雷和双嘧达莫均更高。
- 花生四烯酸抑制在改良组更高(中位75% vs 39%),但ADP抑制无差异。
核心结论
- 使用柏林心脏EXCOR儿童心室辅助装置时,采用三联抗血小板高剂量体重滴定方案较双联抗血小板按血小板功能检测滴定方案,卒中发生率显著降低且不增加出血风险。
研究设计与样本
- 回顾性队列研究,纳入斯坦福大学2009至2014年所有使用EXCOR的儿童,分为埃德蒙顿指南组(N=16)和斯坦福改良指南组(N=11)。
主要发现
- 斯坦福改良指南组卒中发生率为0.8事件/1000支持天,埃德蒙顿指南组为4.9事件/1000支持天,降低84%(p=0.031)。
- 斯坦福改良指南组卒中发生率较既往IDE试验降低86%(p=0.006)。
- 斯坦福改良指南组出血率更低(p=0.015)。
- 阿司匹林、氯吡格雷和双嘧达莫目标剂量更高(所有p<0.003),且剂量变异性更小。
- 花生四烯酸抑制在斯坦福改良指南组更高(中位75% vs 39%,p=0.008),ADP抑制无差异。
关键数值与推荐
- 斯坦福改良指南:常规三联抗血小板治疗,剂量上调至基于体重的高剂量目标,必要时使用低剂量类固醇控制炎症。
- 埃德蒙顿指南:双联抗血小板治疗,剂量根据血栓弹力图/血小板图检测滴定。
临床怎么用
- 对于柏林心脏EXCOR支持的儿童,可考虑采用三联抗血小板高剂量体重滴定方案以降低卒中风险,同时需监测出血。
局限性
- 样本量较小(埃德蒙顿组16例,斯坦福改良组11例),需更大规模研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stroke is the most feared complication associated with the Berlin Heart EXCOR pediatric ventricular assist device (VAD), the most commonly used VAD in children, and affects 1 in 3 children. We sought to determine whether a modified anti-thrombotic guideline, involving more intense platelet inhibition and less reliance on platelet function testing, is associated with a lower incidence of stroke. METHODS: All children supported with the EXCOR at Stanford from 2009 to 2014 were divided into 2 cohorts based on the primary anti-thrombotic guideline used to prevent pump thrombosis: (1) the Edmonton Anti-thrombotic Guideline (EG) cohort, which included children implanted before September 2012 when dual anti-platelet therapy was used with doses titrated to Thromboelastrography/PlateletMapping (TEG/PM); and (2) the Stanford Modified Anti-thrombotic Guideline (SG) cohort, which included children implanted on or after September 2012 when triple anti-platelet therapy was used routinely and where doses were uptitrated to high, weight-based dosing targets, with low-dose steroids administered as needed for inflammation. RESULTS: At baseline, the EG (N = 16) and SG (N = 11) cohorts were similar. The incidence rate of stroke in the SG cohort was 84% lower than in the EG cohort (0.8 vs 4.9 events per 1,000 days of support, p = 0.031), and 86% lower than in the previous Investigational Device Exemption trial (p = 0.006). The bleeding rate was also lower in the SG cohort (p = 0.015). Target doses of aspirin, clopidogrel and dipyridamole were higher (all p < 0.003), with less dosing variability in the SG cohort than in the EG cohort. There was no difference in adenosine diphosphate inhibition by TEG/PM, but arachidonic acid inhibition was higher in the SG cohort (median 75% vs 39%, p = 0.008). CONCLUSIONS: Stroke was significantly less common in pediatric patients supported with the Berlin Heart EXCOR VAD using a triple anti-platelet regimen uptitrated to high, weight-based dosing targets as compared with the dual anti-platelet regimen titrated to PM, and without a higher risk of bleeding. Larger studies are needed to confirm these findings.
引用
- Rosenthal DN, Lancaster CA, McElhinney DB, et al. Impact of a modified anti-thrombotic guideline on stroke in children supported with a pediatric ventricular assist device. J Heart Lung Transplant. 2017. PMID: 28606584. doi:10.1016/j.healun.2017.05.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。